Increlex

Active Ingredient(s): Mecasermin Recombinant
FDA Approved: * August 30, 2005
Pharm Company: * TERCICA
Category: Growth Hormone Treatment

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Increlex Overview

Mecasermin (INN) (brand name Increlex), also known as recombinant human insulin-like growth factor-1 (rhIGF-1), is a recombinant form of human insulin-like growth factor 1 (IGF-I) which is used in the long-term treatment of growth failure and short stature in children with severe primary IGF-I deficiency, for instance due to growth hormone deficiency or Laron syndrome (growth hormone insensitivity).[1][2][3] Mecasermin has a biological half-life...

Read more Increlex Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Mecasermin

Recent Increlex Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Mecasermin Recombinant
  • Injection: 36mg/0.6ml, 40mg/4ml (10mg/ml), 40mg/4ml(10mg/ml)
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Increlex: (1 result)

Sorted by National Drug Code
  • 15054-1040 Increlex 40 mg/4ml Subcutaneous Injection, Solution by Ipsen Biopharmaceuticals, Inc.

Other drugs which contain Mecasermin Recombinant or a similar ingredient: (3 results)